MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202627000797 A) filed by Sun Pharmaceutical Industries Limited on January 05, 2026, for Glp-1 Analog For Use In The Treatment Of Metabolic Disorders.
Inventors include Thennati, Rajamannar; Burade, Vinod Sampatrao; Natarajan, Muthukumaran; Nagaraja, Ravishankara Madavati; Shahi, Pradeep; Panchal, Satishbhai Tribhovanbhai; and Agrawal, Sudeep Kumar.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The disclosure relates to methods of using GLP-1 analog and composition thereof for the treatment of metabolic disorders, such as obesity, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and hypertriglyceridemia. More specifically, the disclosure relates to methods for treating obesity in a subject, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure also relates to methods for treating a metabolic disorder in a subject in need thereof, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes or other metabolic disorder in a subject.
Disclaimer: Curated by HT Syndication.
